October 23 rd , 2019 1
PRIVATE & CONFIDENTIAL LEGAL DISCLAIMER This presentation includes estimates, projections, and other forward-looking statements, within the meaning of applicable Canadian Securities Laws or United States securities legislation. All estimates, projections, and other forward-looking statements have been prepared by us on assumptions we consider reasonable, but these estimates, projections, and statements involve a high degree of risk and may not prove accurate. No representation is made as to the accuracy of such estimates, statements, or projections or their attainability, and nothing in this presentation shall be relied upon as a promise or representation as to our future performance. No general solicitation will be conducted and no offering literature or advertising in any form will or may be employed in the offering of any securities of OG DNA Genetics, Inc. Statements that are not historical facts or that describe our plans, beliefs, goals, intentions, objectives, projections, expectations, assumptions, strategies, or future events are forward-looking statements. In addition, terms such as “will,” “believe,” “anticipate,” “estimate,” “plan,” “projects,” “continuing,” “ongoing,” “expect,” “intend,” “potential,” and similar expressions and discussions of our strategy or other intentions identify forward-looking statements. These statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed for the reasons described in this presentation. You should not place undue reliance on these forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This presentation includes certain statements and estimates provided by the Company with respect to the anticipated future performance of the Company. Such statements and estimates reflect various assumptions by the Company concerning anticipated results, which assumptions may or may not prove to be correct. No representations are made as to the accuracy of such statements and estimates, as well as the exercise of a substantial degree of judgment by management as to the scope and presentation of such information. No representations or warranties are made as to the accuracy of such statements or estimates of expected performance. Actual results achieved during projection periods may differ substantially from those projected. Any representations concerning the Company or its business will be made only by the Company and only in a definitive agreement documenting a transaction between the Company and any prospective party. Certain of the information contained in this presentation concerning industry trends and performance is based upon or derived from information provided by third-party consultants, other industry sources and our research. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of such information and has not independently verified the assumption upon which projections of future trends and performance are based. Statements containing forward-looking information are made as of the date of this presentation. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH JURISDICTION. NO SALES SHALL BE MADE UNTIL THE COMPANY AND THE POTENTIAL INVESTOR ENTERS INTO A SUBSCRIPTION AGREEMENT FOR COMPANY SECURITIES. PROSPECTIVE INVESTORS WILL BE REQUIRED TO MAKE REPRESENTATIONS WITH RESPECT TO THEIR NET WORTH OR INCOME AND TO REPRESENT, AMONG OTHER THINGS, THAT THEY QUALIFY AS “ACCREDITED INVESTORS” AND ARE FAMILIAR WITH AND UNDERSTAND THE TERMS OF THE OFFERING AND HAVE ALL REQUISITE AUTHORITY TO MAKE SUCH INVESTMENT. ANY SECURITIES OF DNA GENETICS HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE . 2
PRIVATE & CONFIDENTIAL COMPANY HIGHLIGHTS – ORIGINAL, AUTHENTIC, PREMIUM 1 Most awarded and sought after cannabis breeder, globally Established in 2004, DNA is one of the largest cannabis brands in the world , 2 with a vast library of in-demand and award-winning strains 3 Expanding licensing & branding platform with some of the largest operators in North America 4 Premium cultivation and processing operations in California 5 Asset-light business model generates strong margins 3
PRIVATE & CONFIDENTIAL HISTORY 4
PRIVATE & CONFIDENTIAL THE BUD BEHIND THE BRANDS 5
PRIVATE & CONFIDENTIAL AWARD WINNING STRAINS 6
PRIVATE & CONFIDENTIAL FOUNDERS Over 200 cannabis awards Multiple Spannabis Don Morris, Chief Cannabis Officer and Aaron Yarkoni, Chief Research Officer are the Emerald Cup highly coveted cultivators and geneticists who established DNA Genetics fifteen years ago High Times Strains of the Year in Amsterdam, the only tolerant market at the time. High Times 100 Most Influential Don and Aaron are synonymous with the DNA brand, and quickly earned DNA its High Times Trail Blazers Award reputation for producing high-quality seeds with unique strain profiles, while inductees simultaneously partnering with governments and medical research groups to drive the High Times Seed Bank Hall of Fame global cannabis movement forward. 7
PRIVATE & CONFIDENTIAL COMPANY OVERVIEW 8
PRIVATE & CONFIDENTIAL MEDIA PRESENCE DISTRIBUTION NETWORK 9
PRIVATE & CONFIDENTIAL THE OPPORTUNITY DNA’s focus has always been to provide customers with unique cannabis strains through effective marketing of the original Dutch and California cannabis cultures. DNA’s brand awareness and award-winning cannabis strains ensure high-yield production, pharmacological efficacy, and heightened consumer interest, making a partnership with DNA Genetics exceedingly valuable. DNA is already expanding aggressively outside of California by partnering with operations that seek a competitive edge, circumventing the time and cost needed to grow organically. DNA uses a robust approach to IP protection , having European and Canadian filings in addition to state-by-state filings pending transition to the national level once cannabis becomes federally legal in the US and elsewhere. Trade secret policies also apply to each agreement to further mitigate IP risk. 10
PRIVATE & CONFIDENTIAL LICENSING PLATFORM cannabis 1 . 11 1 – Pricing data from Ontario Cannabis Store, accessed March 20, 2019
LICENSING PORTFOLIO Pursuant to its US expansion model, DNA has developed various partnerships to license its brand across the legal US states and other countries, partnering with local operations to quickly establish a strong brand presence and product pipeline in newly legalized territories. DNA’s licensing goal is to reach 12 US states and 5 countries by the end of 2020, then 20 states and 10 countries by LICENSED PARTNER 2021. PENDING LICENSEE INTERNAL OPERATIONS 12
LICENSING PIPELINE 13
PRIVATE & CONFIDENTIAL GENETIC DISTRIBUTION Illustrative strain development from base series 14
PRIVATE & CONFIDENTIAL MANAGEMENT Don Morris Founder, Chief Cannabis Officer Aaron Yarkoni Founder, Chief Research Officer Charles Phillips Chief Executive Officer 15
PRIVATE & CONFIDENTIAL MANAGEMENT (cont.) Joshua Hamlin John Walpuck Chief Legal Officer Chief Financial Officer Christopher Cohen Chief Operating Rezwan Khan Officer Vice President, Global Corporate Development Nayir Muñoz Chief Administrative Pedro Cardoso Officer Managing Director, Europe 16
Recommend
More recommend
